Papers
Drug points
Thromboembolism associated with the new contraceptive Yasmin
BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7383.257 (Published 01 February 2003) Cite this as: BMJ 2003;326:257
- Kees van Grootheest (ac.vangrootheest@lareb.nl),
- Tom Vrieling
- Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH ‘s-Hertogenbosch, Netherlands
- Correspondence to: K van Grootheest
Our centre, the Dutch spontaneous reporting system for adverse drug reactions, recently received five reports of thromboembolism as a suspected adverse drug reaction to the new oral contraceptive Yasmin (ethinylestradiol and drospirenone).
A 17 year old woman suddenly collapsed and died after taking the contraceptive for six months. Autopsy showed that she had had a massive pulmonary embolism. No obvious risk factors for thromboembolism, such as smoking, a period of long immobilisation, air flights, or concomitant medication, …